Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 30, 2026Open Access

CRISPR-Based Genome Editing in Sickle Cell Disease: Navigating the Transition from Molecular Triumph to Pediatric Expansion

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMohammed Wassim HammamiUniversity of Sousse

Discussion

Loading...

Member takes

Implication

Randomized trial evaluates CRISPR therapy's effectiveness in children with sickle cell disease, suggesting new treatment possibilities.

Key Points

  • This review explores the shift from managing sickle cell disease to offering a molecular cure through CRISPR-based therapies.
  • Synthesis of CRISPR therapy trajectories for sickle cell disease, focusing on BCL11A disruption.
  • Evaluation of pivotal trials demonstrating effectiveness of exagamglogene autotemcel in adolescents and adults.
  • Discussion of recent FDA expansion of exa-cel to treat children aged two years and older.
  • BCL11A disruption leads to sustained reactivation of fetal hemoglobin, reducing vaso-occlusive crises in treated patients.
  • FDA expansion offers a new treatment avenue for younger patients, potentially preventing irreversible organ damage.
  • Addresses critical barriers such as manufacturing bottlenecks and global access disparities in gene therapy.

Cite This Study

Mohammed Wassim Hammami (2026) studied this question.

synapsesocial.com/papers/6a6b026860e2b924d3ea255fhttps://doi.org/10.5281/zenodo.21640012
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CRISPR-Based Genome Editing in Sickle Cell Disease: Navigating the Transition from Molecular Triumph to Pediatric Expansion2026
  2. 2THERAPEUTIC CRISPR/CAS9 GENOME EDITING TOOL FOR TREATING SICKLE CELL DISEASE2024
  3. 3Translating CRISPR to Practice in the Clinic: Transformative Therapy in Hemoglobinopathies and Emerging Applications in Malignancies2026
  4. 4The Journey of Gene Therapy in Sickle Cell Disease: How Molecular Advances Meet Clinical Care2026
  5. 5Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell therapy to induce fetal hemoglobin for sickle cell disease2024 · 18 citations